Fennec Pharmaceuticals (FENC) Non-Current Debt (2021 - 2022)

Fennec Pharmaceuticals' (FENC) quarterly Non-Current Debt came in at $25.0 million in Q3 2022, up 525.0% on a QoQ basis from $4.0 million in Q2 2022.

Fennec Pharmaceuticals (FENC) Non-Current Debt (2021 - 2022) Analysis & Trends

Fennec Pharmaceuticals (FENC) has 2 years of Non-Current Debt data on file, last reported at $25.0 million in Q3 2022.

Quarterly Non-Current Debt changed N/A year-over-year to $25.0 million in Q3 2022, while the trailing twelve-month figure through Sep 2022 was $25.0 million (changed N/A YoY) and the FY2021 annual result came in at $5.0 million, changed N/A from the prior year.
Non-Current Debt rose to $25.0 million in Q3 2022, from $4.0 million in the prior quarter.
In the past five years, Non-Current Debt ranged from a high of $25.0 million in Q3 2022 to a low of $4.0 million in Q2 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Non-Current Debt (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	1.99 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	-
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	882.16 Mn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	-
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	8.96 Bn
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	-
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	546.77 Mn
10	Fennec Pharmaceuticals	410.60 Mn	369.35 Mn	17.15 Mn	-

Download Data